- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2018
- Public Summary Document (PSD) July 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2018 PBAC Meeting - Word
Pertuzumab – July 2018
Pertuzumab: Solution for I.V. infusion 420 mg in 14 ml; Perjeta®
Last updated
9 November 2018